Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390390 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
A Phase 3 study of Heartburn, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 576
- Enrollment target
- 20
- Study locations
NCT00390390: Completed Phase 3 study of Heartburn, sponsored by Novartis.
NCT00390390 is a Phase 3 study of Heartburn that has completed, run by Novartis. The registered enrollment target is 576 participants, above the 356-participant average among 9 other Heartburn trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390390, a Phase 3 study of Heartburn, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 576 participants
- Enrollment target
- 20
- Study locations
Study Summary
Heartburn, a burning sensation in the chest or throat, occurs in many patients when acidic stomach contents move into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg once a day in treating frequent heartburn.
Conditions Studied
Interventions
- DRUG Lansoprazole
Study Locations (20)
Florida
- Central Florida Clinical Trials inc. - Altamonte Springs
- Tampa Bay Medical Research, Inc. - Clearwater
- Health Awareness Inc. - Jupiter
- University Clinical Research, Inc. - Pembroke Pines
- Palm Beach Research - West Palm Beach
Arizona
- Radiant Research - Chandler
- Radiant Research - Scottsdale - Scottsdale
California
- Edinger Medical Group - Fountain Valley
- Gaslamp Medical Center - San Diego
North Carolina
- Wake research associates, Inc - Raleigh
- Piedmont Medical Research - Winston-Salem
Alabama
- Sunbelt Research Group - Mobile
Alaska
- Arkansas Primary Care Clinic - Little Rock
Colorado
- Expresscare Clinical Research - Colorado Springs
Illinois
- Accelovance - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
What the finished NCT00390390 record still lists
NCT00390390 is an interventional study that assigns participants to a tested intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap, above the 356-participant average among 9 other Heartburn trials with a reported enrollment target (62% higher).
The record links to 1 condition, with Heartburn appearing as the primary indexed condition, and to 1 intervention - of which Lansoprazole is the first listed.
NCT00390390 names 20 study sites across 13 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00390390 about?
NCT00390390 is a clinical study titled "Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn". Heartburn, a burning sensation in the chest or throat, occurs in many patients when acidic stomach contents move into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg once a day in treating frequent heartburn.
What is the current status of trial NCT00390390?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 576 participants. The study started on 2006-06. Estimated completion is 2007-01.
What conditions does trial NCT00390390 study?
This clinical trial studies the following conditions: Heartburn.
What interventions are being tested in trial NCT00390390?
The interventions under investigation include: Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00390390?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390390 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heartburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00390390's enrollment target sits among peer trials
576 4th of 9 higher than 5 of 9 other Heartburn trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heartburn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia